Evaluation of vancomycin-Resistant Enterococci (VRE)-associated morbidity following relaxation of VRE screening and isolation precautions in a tertiary care hospital

Infection Control and Hospital Epidemiology

Volumn 35, Issue 7, 2014, Pages 818-825

  Popiel, Kristin Y ^a   Miller, Mark A ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SCREENING TEST; TERTIARY CARE CENTER; VANCOMYCIN RESISTANT ENTEROCOCCUS; CANADA; CROSS INFECTION; DRUG EFFECTS; EVALUATION STUDY; FACTUAL DATABASE; GRAM-POSITIVE BACTERIAL INFECTIONS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; PATIENT CARE; TEACHING HOSPITAL;

BACTEREMIA; CROSS INFECTION; DATABASES, FACTUAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALS, TEACHING; HUMANS; INFECTION CONTROL; PATIENT ISOLATION; POLYMERASE CHAIN REACTION; QUEBEC; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; VANCOMYCIN; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84902959491     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/676860     Document Type: Article

References (41)

1. Lior L, Litt M, Hockin J, et al. Vancomycin-resistant enterococci on a renal ward in an Ontario hospital. Can Commun Dis Rep 1996;22(15):125-128.
2. Fortin A, Milord F, Guay M, d'Halewyn MA, Vigeant P, Leblanc G. First known outbreak of colonizing vancomycin-resistant enterococci in Quebec. Can Commun Dis Rep 1998;24(11):85-94.
3. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin- resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348(14):1342-1347.
4. McCracken M, Wong A, Mitchell R, et al. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. J Antimicrob Chemother 2013;68(7):1505-1509.
5. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46(5):668-674.
6. Zhu W, Clark N, Patel JB. pSK41-like plasmid is necessary for Inc18-like vanA plasmid transfer from Enterococcus faecalis to Staphylococcus aureus in vitro. Antimicrob Agents Chemother 2013;57(1):212-219.
7. Foucault ML, Courvalin P, Grillot-Courvalin C. Fitness cost of vanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53(6):2354-2359.
8. Lloyd-Smith P, Younger J, Lloyd-Smith E, Green H, Leung V, Romney MG. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay. J Hosp Infect 2013;85(1):54-59.
9. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24(5):362-386.
10. Escaut L, Bouam S, Frank-Soltysiak M, et al. Eradication of an outbreak of vancomycin-resistant Enterococcus (VRE): the cost of a failure in the systematic screening. Antimicrob Resist Infect Control 2013;2(1):18.
11. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007;35(10 suppl 2):S165-S193.
12. Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 2011;364(15):1407-1418.
13. Derde LP, Cooper BS, Goossens H, et al. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet 2014;14(1):31-39.
14. Perugini MR, Nomi SM, Lopes GK, et al. Impact of the reduction of environmental and equipment contamination on vancomycin- resistant enterococcus rates. Infection 2011;39(6):587-593.
15. Mutters NT, Mersch-Sundermann V, Mutters R, Brandt C, Schneider-Brachert W, Frank U. Control of the spread of vancomycin- resistant enterococci in hospitals: epidemiology and clinical relevance. Dtsch Arztebl Int 2013;110(43):725-731.
16. Response to the Provincial Infectious Diseases Advisory Committee Review of Literature for Evidence-Based Best Practices for VRE Control. London, Ontario: St. Joseph's Health Care London, 2012. http://www.sjhc.london.on.ca/sites/default/files/pdf/VRE_response.pdf. Accessed September 18, 2013.
17. Park I, Park RW, Lim SK, et al. Rectal culture screening for vancomycin-resistant enterococcus in chronic haemodialysis patients: false-negative rates and duration of colonisation. J Hosp Infect 2011;79(2):147-150.
18. Mak A, Miller MA, Chong G, Monczak Y. Comparison of PCR and culture for screening of vancomycin-resistant Enterococci: highly disparate results for vanA and vanB. J Clin Microbiol 2009; 47(12):4136-4137.
19. Werner G, Klare I, Fleige C, et al. Vancomycin-resistant vanBtype Enterococcus faecium isolates expressing varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU. Antimicrob Resist Infect Control 2012;1(1):21.
20. Ridwan B, Mascini E, van Der Reijden N, Verhoef J, Bonten M. What action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals? BMJ 2002; 324(7338):666-668.
21. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23(6):1234-1239.
22. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162(19):2223-2228.
23. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for con- trolling vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002;23(8):429-435.
24. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158(5):522-527.
25. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin- resistant enterococci. Clin Infect Dis 2002;35(10):1139-1146.
26. Stroud L, Edwards J, Danzing L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal bloodstream infections. Infect Control Hosp Epidemiol 1996;17(9):576-580.
27. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control 2006;34(8):534-536.
28. Miller M, Bernard L, Thompson M, Grima D, Pepin J. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2010;31(7):710-715.
29. Almyroudis NG, Lesse AJ, Hahn T, et al. Molecular epidemiology and risk factors for colonization by vancomycin-resistant Enterococcus in patients with hematologic malignancies. Infect Control Hosp Epidemiol 2011;32(5):490-496.
30. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl JMed 2000;343(26):1925-1932.
31. Bar K, Wisplinghoff H, Wenzel RP, Bearman GM, Edmond MB. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci. BMC Infect Dis 2006;6:145.
32. Perencevich EN, Fisman DN, Lipsitch M, Harris AD, Morris JG Jr, Smith DL. Projected benefits of active surveillance for vancomycin- resistant enterococci in intensive care units. Clin Infect Dis 2004;38(8):1108-1115.
33. Tacconelli E, Cataldo MA. Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents 2008; 31(2):99-106.
34. Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003;37(7):921-928.
35. Saint S, Higgins LA, Nallamothu BK, Chenoweth C. Do physicians examine patients in contact isolation less frequently? a brief report. Am J Infect Control 2003;31(6):354-356.
36. Catalano G, Houston SH, Catalano MC, et al. Anxiety and depression in hospitalized patients in resistant organism isolation. South Med J 2003;96(2):141-145.
37. Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA 2003;290(14):1899-1905.
38. Calderwood MS, Mauer A, Tolentino J, et al. Epidemiology of vancomycin-resistant enterococci among patients on an adult stem cell transplant unit: observations from an active surveillance program. Infect Control Hosp Epidemiol 2008;29(11):1019-1025.
39. Yoo SJ, Sung H, Cho YU, Kim MN, Pai CH, Kim YS. Role of horizontal transfer of the transposon Tn1546 in the nosocomial spread of vanA vancomycin-resistant enterococci at a tertiary care hospital in Korea. Infect Control Hosp Epidemiol 2006; 27(10):1081-1087.
40. Rice LB, Lakticova V, Carias LL, Rudin S, Hutton R, Marshall SH. Transferable capacity for gastrointestinal colonization in Enterococcus faecium in a mouse model. J Infect Dis 2009;199(3): 342-349.
41. Miller MA. Revised VRE Protocol. Montreal: Jewish General Hospital, 2010.